Thermo Fisher Scientific (TMO) Q1 FY2026 earnings: revenue $11.0 billion, up 6.2% on the year
Thermo Fisher Scientific Inc. (TMO) reported revenue of $11.0 billion for Q1 FY2026, the quarter ended 28 March 2026, up 6.2% on the same quarter a year earlier. Net income was $1.7 billion, up 9.6% on the year, and diluted earnings per share $4.43. The figures are the company's own, from the 10-Q it filed with the SEC on 1 May 2026.
Revenue
$11.0 billion
+6.2% on the year · -9.9% on the quarter
Q2 FY2024Q1 FY2026
Operating margin
16.9%
16.6% a year earlier
Q2 FY2024Q1 FY2026
Net income
$1.7 billion
+9.6% on the year · -15.9% on the quarter
Q2 FY2024Q1 FY2026
Diluted EPS
$4.43
+11.3% on the year · -15.0% on the quarter
Q2 FY2024Q1 FY2026
this quarterthe same quarter a year earlierHover a bar for its figure.
What management said
Revenue grew 6%, organic growth 1%: Revenue rose to $11.01 billion from $10.36 billion. Acquisitions added 3 points and currency translation 2 points, leaving organic growth at 1%.
Adjusted EPS rose 6% to $5.44: Adjusted EPS was $5.44 against $5.15 a year earlier. Adjusted net income was $2,027 million, against $1,950 million.
Life Sciences Solutions revenue rose: Revenue was $2,636 million against $2,341 million. Segment income was $954 million at a 36.2% margin, against $834 million and 35.6%.
$ million except per share. Read moreFourth quarters are the year less the first three quarters. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
Q1 FY2026
Q4 FY2025
Q1 FY2025
On the quarter
On the year
Last 8 quarters
Operating cash flow
1,192
3,457
723
-65.5%
+64.9%
Capital expenditure
376
465
362
-19.1%
+3.9%
Free cash flow
816
2,992
361
-72.7%
+126.0%
Free cash flow margin
7.4%
24.5%
3.5%
Cash from investing
-8,961
891
-527
Cash from financing
1,093
3,526
-102
-69.0%
Depreciation and amortisation
736
728
705
+1.1%
+4.4%
Share-based compensation
83.0
84.0
75.0
-1.2%
+10.7%
Buybacks
3,000
37.0
2,000
+8,008.1%
+50.0%
Dividends paid
162
162
149
0.0%
+8.7%
Dividend per share
$0.47
n/a
$0.43
+9.3%
Diluted shares, weighted
373m
377m
379m
-1.1%
-1.6%
Shares outstanding at period end
372m
371m
377m
+0.0%
-1.6%
Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.
Balance sheet
$ million
Q1 FY2026
Q4 FY2025
Q1 FY2025
On the quarter
On the year
Last 8 quarters
Shareholders' equity
51,934
53,407
49,390
-2.8%
+5.2%
Non-controlling interest
7.0
7.0
-33.0
0.0%
Redeemable equity
121
122
128
-0.8%
-5.5%
Debt
42,947
39,385
34,189
+9.0%
+25.6%
Operating lease liabilities
n/a
1,195
n/a
Other liabilities
18,272
16,227
15,367
+12.6%
+18.9%
Total liabilities and equity
113,281
110,343
99,041
+2.7%
+14.4%
Fixed assets
10,658
10,565
9,331
+0.9%
+14.2%
Goodwill
55,187
49,362
46,493
+11.8%
+18.7%
Intangible assets
19,146
15,838
15,323
+20.9%
+24.9%
Investments
2.0
253
1,813
-99.2%
-99.9%
Cash and equivalents
3,254
9,852
4,134
-67.0%
-21.3%
Receivables
9,204
8,900
8,455
+3.4%
+8.9%
Inventory
5,496
5,425
5,224
+1.3%
+5.2%
Other assets
10,334
10,148
8,268
+1.8%
+25.0%
Total assets
113,281
110,343
99,041
+2.7%
+14.4%
Questions
What was Thermo Fisher Scientific's revenue in Q1 FY2026?
Thermo Fisher Scientific (TMO) reported revenue of $11.0 billion for Q1 FY2026, the quarter ended 28 March 2026, up 6.2% on the same quarter a year earlier.
How much did Thermo Fisher Scientific earn in Q1 FY2026?
Net income for Q1 FY2026 was $1.7 billion, up 9.6% on the year, and diluted earnings per share $4.43.
When did Thermo Fisher Scientific report Q1 FY2026 results?
Thermo Fisher Scientific filed its 10-Q for the quarter ended 28 March 2026 with the SEC on 1 May 2026.
Each quarter as filed, linked to its filing. Read more* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS, and its diluted share count where shown, are from the company's results press release for that quarter, checked against the company's filed figures or a second data source. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.
10-Q for the period ended 28 March 2026, filed 1 May 2026: the filing.